Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reality Check On UK Production Capacity For COVID-19 Treatments

Debate Shifts From Treatments To Scalability, Manufacturing Capacity, And Delivery

Executive Summary

In the first of a two-part series of articles on the UK COVID-19 Therapeutics Task Force, the Pink Sheet reports on how task force members are examining the role of therapeutics in tackling the pandemic and why the UK’s manufacturing capability needs to be strengthened so it can meet future demand. The second article will cover the work of the task force and how it is structured to identify and advance promising coronavirus treatments

You may also be interested in...



Coronavirus Notebook: EU Strikes Deals For Gilead’s Veklury, Janssen’s Vaccine

Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics. 

UK 'Punching Above Its Weight' On Coronavirus Therapeutics

In the second instalment of a two-part article, members of the UK COVID-19 Therapeutics Task Force look at the various therapies currently under investigation for coronavirus patients and explain how the task force coordinates and advances the research projects being conducted under its aegis. 

EU Politicians: 'Bring Pharma Manufacturing Back To Europe'

The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation. 

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel